Insulin-like growth factor - Oestradiol crosstalk and mammary gland tumourigenesis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 2, 2013, Pages 345-353

  Hawsawi, Yousef ^a   El Gendy, Reem ^a   Twelves, Christopher ^b   Speirs, Valerie ^c   Beattie, James ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Breast cancer; Endocrine resistance; Insulin like growth factor; Oestradiol

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; INSULIN; INSULIN RECEPTOR SUBSTRATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; TAMOXIFEN; VITAMIN D DERIVATIVE;

APOPTOSIS; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; CELL ADHESION; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE TRANSPORT; CELL MIGRATION; CHEMOTAXIS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DNA SYNTHESIS; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HORMONAL REGULATION; HORMONE ACTION; HORMONE PROTEIN COMPLEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAMMARY GLAND FUNCTION; MITOGENESIS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; TUMOR GROWTH;

BREAST CANCER; ENDOCRINE RESISTANCE; INSULIN-LIKE GROWTH FACTOR; OESTRADIOL;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84887589981     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.10.005     Document Type: Review

References (152)

1. Perks C.M., Holly J.M. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J. Mammary Gland Biol. Neoplasia 2008, 13(4):455-469.
2. Rowzee A.M., et al. IGF ligand and receptor regulation of mammary development. J. Mammary Gland Biol. Neoplasia 2008, 13(4):361-370.
3. Wilson E.M., Oh Y., Rosenfeld R.G. Generation and characterization of an IGFBP-7 antibody: identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J. Clin. Endocrinol. Metab. 1997, 82(4):1301-1303.
4. Yang D.H., et al. Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells. J. Clin. Endocrinol. Metab. 1998, 83(7):2593-2596.
5. Sano A., et al. Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int. J. Oncol. 2007, 30(6):1493-1498.
6. Leong S.R., et al. Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding protein complex. Mol. Endocrinol. 1992, 6(6):870-876.
7. Zapf J., Schmid C., Froesch E.R. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin. Endocrinol. Metab. 1984, 13(1):3-30.
8. Espelund U., et al. Elevated free IGF2 levels in localized, early-stage breast cancer in women. Eur. J. Endocrinol. 2008, 159(5):595-601.
9. Morgan D.O., et al. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987, 329(6137):301-307.
10. Blakesley V.A., et al. Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling?. Cytokine Growth Factor Rev. 1996, 7(2):153-159.
11. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J. Mol. Endocrinol. 2011, 47(1):R1-R10.
12. McCaig C., Perks C.M., Holly J.M. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J. Cell Sci. 2002, 115(Pt 22):4293-4303.
13. Chen J.C., et al. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J. Cell. Physiol. 1994, 158(1):69-78.
14. McIntosh J., et al. IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. J. Biol. Chem. 2010, 285(50):38788-38800.
15. Butt A.J., et al. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J. Biol. Chem. 2003, 278(32):29676-29685.
16. Salahifar H., Baxter R.C., Martin J.L. Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction. Endocrinology 1997, 138(4):1683-1690.
17. Oh Y., et al. Insulin-like growth factor binding protein (IGFBP)-3 levels in conditioned media of Hs578T human breast cancer cells are post-transcriptionally regulated. Growth Regul. 1993, 3(1):84-87.
18. Carboni J.M., et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 2009, 8(12):3341-3349.
19. Minuto F., et al. Partial characterization of somatomedin C-like immunoreactivity secreted by breast cancer cells in vitro. Mol. Cell. Endocrinol. 1987, 54(2-3):179-184.
20. Huff K.K., et al. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res. 1986, 46(9):4613-4619.
21. De Leon D.D., et al. Demonstration of insulin-like growth factor (IGF-I and -II) receptors and binding protein in human breast cancer cell lines. Biochem. Biophys. Res. Commun. 1988, 152(1):398-405.
22. Ahmed S.R., et al. Characterization and hormonal regulation of radioimmunoassayable IGF-I (insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells. Anticancer Res. 1990, 10(5A):1217-1223.
23. De Leon D.D., et al. Insulin-like growth factor binding proteins in human breast cancer cells: relationship to hIGFBP-2 and hIGFBP-3. J. Clin. Endocrinol. Metab. 1990, 71(2):530-532.
24. Rohlik Q.T., et al. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem. Biophys. Res. Commun. 1987, 149(1):276-281.
25. Freed K.A., Herington A.C. Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture. J. Mol. Endocrinol. 1989, 3(3):183-190.
26. Yee D., et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol. Endocrinol. 1989, 3(3):509-517.
27. Yee D., et al. Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res. 1988, 48(23):6691-6696.
28. Furlanetto R.W., DiCarlo J.N. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res. 1984, 44(5):2122-2128.
29. Karey K.P., Sirbasku D.A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 1988, 48(14):4083-4092.
30. Lippman M.E., et al. Autocrine and paracrine growth regulation of human breast cancer. J. Steroid Biochem. 1986, 24(1):147-154.
31. Osborne C.K., Clemmons D.R., Arteaga C.L. Regulation of breast cancer growth by insulin-like growth factors. J. Steroid Biochem. Mol. Biol. 1990, 37(6):805-809.
32. Pollak M.N., et al. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem. Biophys. Res. Commun. 1988, 154(1):326-331.
33. Gooch J.L., Van Den Berg C.L., Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res. Treat. 1999, 56(1):1-10.
34. Arteaga C.L. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat. 1992, 22(1):101-106.
35. Arteaga C.L., et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest. 1989, 84(5):1418-1423.
36. Arteaga C.L., Osborne C.K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989, 49(22):6237-6241.
37. Cullen K.J., et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990, 50(1):48-53.
38. Manni A., Wright C., Buck H. Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar. Breast Cancer Res. Treat. 1991, 20(1):43-52.
39. Neuenschwander S., Roberts C.T., LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995, 136(10):4298-4303.
40. De Leon D.D., et al. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors 1992, 6(4):327-336.
41. Milazzo G., et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992, 52(14):3924-3930.
42. Yee D., et al. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ. 1994, 5(1):73-77.
43. Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res. Treat. 1994, 32(1):85-95.
44. Beattie J., et al. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem. J. 2006, 395(1):1-19.
45. De Leon D.D., et al. Characterization of insulin-like growth factor binding proteins from human breast cancer cells. Mol. Endocrinol. 1989, 3(3):567-574.
46. McGuire W.L., et al. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J. Natl. Cancer Inst. 1992, 84(17):1336-1341.
47. Sheikh M.S., et al. Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells. Biochem. Biophys. Res. Commun. 1992, 183(3):1003-1010.
48. Dubois V., et al. Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium. Eur. J. Biochem. 1995, 232(1):47-53.
49. Kim I., et al. Identification and regulation of insulin-like growth factor binding proteins produced by hormone-dependent and -independent human breast cancer cell lines. Mol. Cell. Endocrinol. 1991, 78(1-2):71-78.
50. Huynh H., Yang X., Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem. 1996, 271(2):1016-1021.
51. Martin J.L., et al. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 1995, 136(3):1219-1226.
52. Pratt S.E., Pollak M.N. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res. 1993, 53(21):5193-5198.
53. Adamo M.L., et al. Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 1992, 131(4):1858-1866.
54. Muck C., et al. Role of insulin-like growth factor binding protein-3 in human umbilical vein endothelial cell senescence. Rejuvenation Res. 2008, 11(2):449-453.
55. Baege A.C., Disbrow G.L., Schlegel R. IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis. J. Virol. 2004, 78(11):5720-5727.
56. Goldstein S., Moerman E.J., Baxter R.C. Accumulation of insulin-like growth factor binding protein-3 in conditioned medium of human fibroblasts increases with chronologic age of donor and senescence in vitro. J. Cell. Physiol. 1993, 156(2):294-302.
57. Bentel J.M., et al. Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells. J. Cell. Physiol. 1995, 165(1):212-221.
58. Sheikh M.S., et al. Retinoic acid and estrogen modulation of insulin-like growth factor binding protein-4 gene expression and the estrogen receptor status of human breast carcinoma cells. Biochem. Biophys. Res. Commun. 1993, 193(3):1232-1238.
59. Sheikh M.S., et al. Insulin-like growth factor binding protein-5 gene expression is differentially regulated at a post-transcriptional level in retinoic acid-sensitive and resistant MCF-7 human breast carcinoma cells. Biochem. Biophys. Res. Commun. 1992, 188(3):1122-1130.
60. Fontana J.A., et al. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 1991, 128(2):1115-1122.
61. Klotz D.M., et al. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J. Biol. Chem. 2002, 277(10):8531-8537.
62. Richards R.G., et al. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(21):12002-12007.
63. Casa A.J., et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res. Treat. 2012, 132(1):61-73.
64. Osborne C.K., Hobbs K., Clark G.M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985, 45(2):584-590.
65. Jiralerspong S., et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 2009, 27(20):3297-3302.
66. Goodwin P.J., Ligibel J.A., Stambolic V. Metformin in breast cancer: time for action. J. Clin. Oncol. 2009, 27(20):3271-3273.
67. Pritchard K.I., et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J. Clin. Oncol. 2011, 29(29):3869-3876.
68. Ruan W., et al. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995, 136(3):1296-1302.
69. Atsriku C., et al. Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol. Cell. Proteomics 2009, 8(3):467-480.
70. Shukla V., et al. IGF signaling pathway as a selective target of familial breast cancer therapy. Curr. Mol. Med. 2008, 8(8):727-740.
71. Sachdev D. Regulation of breast cancer metastasis by IGF signaling. J. Mammary Gland Biol. Neoplasia 2008, 13(4):431-441.
72. Fox E.M., et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011, 71(21):6773-6784.
73. Mawson A., et al. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol. Cell. Endocrinol. 2005, 229(1-2):161-173.
74. Martin M.B., et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000, 141(12):4503-4511.
75. Song R.X., et al. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(7):2076-2081.
76. Kato S., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270(5241):1491-1494.
77. Simoncini T., et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407(6803):538-541.
78. Morelli C., et al. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 2003, 22(26):4007-4016.
79. Song R.X., et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol. Endocrinol. 2002, 16(1):116-127.
80. Castoria G., et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001, 20(21):6050-6059.
81. Kahlert S., et al. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 2000, 275(24):18447-18453.
82. Lee Y.R., et al. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem. Biophys. Res. Commun. 2005, 336(4):1221-1226.
83. Sisci D., et al. The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann. Oncol. 2007, 18(Suppl. 6):vi81-vi85.
84. Becker M.A., et al. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol. Endocrinol. 2011, 25(3):516-528.
85. Chen D., et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell 2000, 6(1):127-137.
86. Joel P.B., Traish A.M., Lannigan D.A. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J. Biol. Chem. 1998, 273(21):13317-13323.
87. Medunjanin S., et al. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J. Biol. Chem. 2005, 280(38):33006-33014.
88. Tian J., et al. Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice. J. Clin. Invest. 2012, 122(1):192-204.
89. Barone I., et al. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene 2010, 29(16):2404-2414.
90. Cui Y., et al. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004, 64(24):9199-9208.
91. Murphy L.C., et al. The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J. Steroid Biochem. Mol. Biol. 2009, 114(1-2):90-95.
92. Murphy L.C., Seekallu S.V., Watson P.H. Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer 2011, 18(1):R1-R14.
93. Foulstone E.J., et al. Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology 2013, 154(5):1780-1793.
94. Hermani A., et al. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-alpha activation in breast cancer cells in an IGF-independent manner. Cell. Signal. 2013, 25(6):1395-1402.
95. Huynh H., Yang X.F., Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ. 1996, 7(11):1501-1506.
96. Tharakan R., et al. Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Mol. Cell. Endocrinol. 2008, 295(1-2):70-78.
97. Thomas R.S., et al. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J. Mol. Endocrinol. 2008, 40(4):173-184.
98. Gee J.M., et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr. Relat. Cancer 2005, 12(Suppl. 1):S99-S111.
99. Murphy L.C., et al. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clin. Cancer Res. 2004, 10(17):5902-5906.
100. Tsonis A.I., et al. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS J. 2013, 280(10):2248-2259.
101. Kamanga-Sollo E., et al. Role of estrogen receptor-alpha (ESR1) and the type 1 insulin-like growth factor receptor (IGFR1) in estradiol-stimulated proliferation of cultured bovine satellite cells. Domest. Anim. Endocrinol. 2013, 44(1):36-45.
102. Pandini G., et al. 17beta-Estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells. Cancer Res. 2007, 67(18):8932-8941.
103. Mendoza R.A., et al. Interactions between IGF-I, estrogen receptor-alpha (ERalpha), and ERbeta in regulating growth/apoptosis of MCF-7 human breast cancer cells. J. Endocrinol. 2011, 208(1):1-9.
104. Picard N., et al. Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta. Mol. Endocrinol. 2008, 22(2):317-330.
105. Tremblay A., et al. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell 1999, 3(4):513-519.
106. Peng B., et al. Putative functional characteristics of human estrogen receptor-beta isoforms. J. Mol. Endocrinol. 2003, 30(1):13-29.
107. Carmeci C., et al. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997, 45(3):607-617.
108. Prossnitz E.R., et al. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu. Rev. Physiol. 2008, 70:165-190.
109. De Marco P., et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene 2013, 32(6):678-688.
110. Akekawatchai C., et al. Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J. Biol. Chem. 2005, 280(48):39701-39708.
111. Yee D., et al. The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. Cancer Treat. Res. 1991, 53:93-106.
112. Koos R.D. Minireview: putting physiology back into estrogens' mechanism of action. Endocrinology 2011, 152(12):4481-4488.
113. Stewart A.J., et al. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 1990, 265(34):21172-21178.
114. Clarke R.B., Howell A., Anderson E. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br. J. Cancer 1997, 75(2):251-257.
115. Huynh H., et al. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin. Cancer Res. 1996, 2(12):2037-2042.
116. Westley B.R., May F.E. Role of insulin-like growth factors in steroid modulated proliferation. J. Steroid Biochem. Mol. Biol. 1994, 51(1-2):1-9.
117. Maor S., et al. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J. Endocrinol. 2006, 191(3):605-612.
118. Genua M., et al. Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. Cancer Res. 2009, 69(18):7270-7277.
119. Thorsen T., et al. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I. J. Steroid Biochem. Mol. Biol. 1992, 41(3-8):537-540.
120. Mathieu M., et al. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol. Endocrinol. 1991, 5(6):815-822.
121. Osborne C.K., et al. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol. Endocrinol. 1989, 3(11):1701-1709.
122. Song R.X., et al. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007, 148(8):4091-4101.
123. Santen R.J., et al. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 2009, 74(7):586-594.
124. Song R.X., et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J. Steroid Biochem. Mol. Biol. 2010, 118(4-5):219-230.
125. Gibson S.L., Ma Z., Shaw L.M. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007, 6(6):631-637.
126. Panno M.L., et al. Evidence that the mouse insulin receptor substrate-1 belongs to the gene family on which the promoter is activated by estrogen receptor alpha through its interaction with Sp1. J. Mol. Endocrinol. 2006, 36(1):91-105.
127. Lee A.V., et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 1999, 13(5):787-796.
128. Gaben A.M., et al. Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer 2012, 12:291.
129. Figueroa J.A., Yee D. The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. Breast Cancer Res. Treat. 1992, 22(1):81-90.
130. Wiseman L.R., et al. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur. J. Cancer 1993, 29A(16):2256-2264.
131. Knowlden J.M., et al. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005, 146(11):4609-4618.
132. Massarweh S., et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006, 66(16):8266-8273.
133. Parisot J.P., et al. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer 1999, 79(5-6):693-700.
134. Boylan M., van den Berg H.W., Lynch M. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann. Oncol. 1998, 9(2):205-211.
135. Gualberto A., Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28(34):3009-3021.
136. van den Berg H.W., et al. Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br. J. Cancer 1996, 73(4):477-481.
137. Fan P., et al. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res. 2007, 67(3):1352-1360.
138. Robertson J.F., et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013, 14(3):228-235.
139. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J. Natl. Cancer Inst. 2012, 104(13):975-981.
140. Fagan D.H., et al. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. 2012, 72(13):3372-3380.
141. Naing A., et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin. Cancer Res. 2012, 18(9):2625-2631.
142. Ghayad S.E., Cohen P.A. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat. Anticancer Drug Discov. 2010, 5(1):29-57.
143. McCotter D., et al. Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. Cancer Lett. 1996, 99(2):239-245.
144. Maxwell P., van den Berg H.W. Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett. 1999, 139(2):121-127.
145. Phillips K., et al. Hormonal control of IGF-binding protein (IGFBP)-5 and IGFBP-2 secretion during differentiation of the HC11 mouse mammary epithelial cell line. J. Mol. Endocrinol. 2003, 31(1):197-208.
146. Ahn B.Y., et al. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res. 2010, 70(8):3013-3019.
147. Perks C.M., et al. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J. Cell. Biochem. 1999, 75(4):652-664.
148. Fowler C.A., et al. Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int. J. Cancer 2000, 88(3):448-453.
149. Burrows C., et al. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 2006, 147(7):3484-3500.
150. Davidson N.E., et al. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol. Endocrinol. 1987, 1(3):216-223.
151. Dickson R.B., et al. Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986, 118(1):138-142.
152. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 2003, 17(3):309-317.